glp 1 drugs and gastroparesis Gastrointestinal effect adverse effects of GLP-1 receptor agonist Incidence of Gastroparesis with GLP-1

These agents are also associated with a minimal risk of hypoglycemia when used as monotherapy or as add-on to metformin monotherapy, but they can contribute to hypoglycemia when used in combination with medications associated with hypoglycemia, such as insulin and insulin secretagogues

The risk of hypoglycemia with GLP-1 RAs is low when used as monotherapy

Recent Developments: Initiated Phase 3 trials for orforglipron, aiming to provide an oral alternative to injectable GLP-1 drugs

Further experiments are needed to understand if the drugs directly contribute to tumorigenesis or if the effects are limited to non-neoplastic cellular proliferation

In this trial, 17,604 patients were enrolled to receive semaglutide 2.4 mg weekly or placebo and followed for approximately 36 months

[DOI] [PubMed] [Google Scholar] 139.Lee JY, et al